Keywords: gilead, hepsera, performs, well, long-term, hep, trial

Gilead's Hepsera performs well in long-term hep B trial

Article | 01 May 2006

Print This

USA-based biopharmaceutical company Gilead Sciences says that the results of a long-term study of its oral antiviral drug Hepsera (adefovir ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in